OA10696A - Utilisation de dérivés tricycliques du 1,4-dihydro-1,4-dioxo 1h-naphtalène, nouveaux composés obtenus et leur application en thérapeutique. - Google Patents

Utilisation de dérivés tricycliques du 1,4-dihydro-1,4-dioxo 1h-naphtalène, nouveaux composés obtenus et leur application en thérapeutique. Download PDF

Info

Publication number: OA10696A
Authority: OA; OAPI
Prior art keywords: dihydro; dioxo; thiazole; new product; naphtho
Prior art date: 1995-12-12

Application number

OA9800080A

Other languages

English (en)

French (fr)

Inventor

Odile Boutherin-Falson

Stephanie Desquand-Billiald

Anita Favrou

Michel Finet

Olivier Tembo

Jean Luc Torregrosa

Sylvie Yannic-Arnoult

Marquer Florence Domagala-Le

Original Assignee

Innothera Lab Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-12

Filing date

1998-06-12

Publication date

2002-11-26

1998-06-12 Application filed by Innothera Lab Sa filed Critical Innothera Lab Sa

2002-11-26 Publication of OA10696A publication Critical patent/OA10696A/fr

Links

150000001875 compounds Chemical class 0.000 title claims description 42
230000001225 therapeutic effect Effects 0.000 title abstract description 3
150000003839 salts Chemical class 0.000 claims abstract description 19
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 13
125000003118 aryl group Chemical group 0.000 claims abstract description 9
125000001072 heteroaryl group Chemical group 0.000 claims abstract description 9
230000002757 inflammatory effect Effects 0.000 claims abstract description 8
206010030113 Oedema Diseases 0.000 claims abstract description 5
201000010099 disease Diseases 0.000 claims abstract description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
125000005843 halogen group Chemical group 0.000 claims abstract description 4
239000001257 hydrogen Substances 0.000 claims abstract description 4
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 4
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 3
125000005842 heteroatom Chemical group 0.000 claims abstract description 3
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 15
239000003814 drug Substances 0.000 claims description 13
VTVVATVHWHSKRM-UHFFFAOYSA-N 8-methoxy-2-phenylbenzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C=3C(OC)=CC=CC=3C(=O)C=2N=C1C1=CC=CC=C1 VTVVATVHWHSKRM-UHFFFAOYSA-N 0.000 claims description 9
230000004872 arterial blood pressure Effects 0.000 claims description 9
RIGRHQRUQGLHKC-UHFFFAOYSA-N 2-amino-3-bromo-6-fluoronaphthalene-1,4-dione Chemical compound FC1=CC=C2C(=O)C(N)=C(Br)C(=O)C2=C1 RIGRHQRUQGLHKC-UHFFFAOYSA-N 0.000 claims description 7
125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 7
BQHURORABWQSBR-UHFFFAOYSA-N 2-amino-3-chloro-6-methylnaphthalene-1,4-dione Chemical compound O=C1C(N)=C(Cl)C(=O)C2=CC(C)=CC=C21 BQHURORABWQSBR-UHFFFAOYSA-N 0.000 claims description 6
CKMGFAPTTIUTOR-UHFFFAOYSA-N 3-amino-2-bromo-5-methoxynaphthalene-1,4-dione Chemical compound O=C1C(Br)=C(N)C(=O)C2=C1C=CC=C2OC CKMGFAPTTIUTOR-UHFFFAOYSA-N 0.000 claims description 6
OLRLFLYEECOSIQ-UHFFFAOYSA-N 3-amino-2-bromo-6-fluoronaphthalene-1,4-dione Chemical compound C1=C(F)C=C2C(=O)C(N)=C(Br)C(=O)C2=C1 OLRLFLYEECOSIQ-UHFFFAOYSA-N 0.000 claims description 6
JUOYZQOSMGRKEA-UHFFFAOYSA-N 5-methoxy-2-phenylbenzo[f][1,3]benzothiazole-4,9-dione Chemical compound N=1C=2C(=O)C=3C(OC)=CC=CC=3C(=O)C=2SC=1C1=CC=CC=C1 JUOYZQOSMGRKEA-UHFFFAOYSA-N 0.000 claims description 6
QAEKLBWGHLEVTE-UHFFFAOYSA-N 7-methoxy-2-phenylbenzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C3=CC(OC)=CC=C3C(=O)C=2N=C1C1=CC=CC=C1 QAEKLBWGHLEVTE-UHFFFAOYSA-N 0.000 claims description 6
229910052760 oxygen Inorganic materials 0.000 claims description 6
PYQLLNKOBQDNOD-UHFFFAOYSA-N 2,3-dibromo-5-methoxynaphthalene-1,4-dione Chemical group O=C1C(Br)=C(Br)C(=O)C2=C1C=CC=C2OC PYQLLNKOBQDNOD-UHFFFAOYSA-N 0.000 claims description 5
LYVAXRGHTGGEBJ-UHFFFAOYSA-N 2-amino-3-bromo-5-methoxynaphthalene-1,4-dione Chemical compound O=C1C(N)=C(Br)C(=O)C2=C1C=CC=C2OC LYVAXRGHTGGEBJ-UHFFFAOYSA-N 0.000 claims description 5
206010040070 Septic Shock Diseases 0.000 claims description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
239000001301 oxygen Substances 0.000 claims description 5
230000036303 septic shock Effects 0.000 claims description 5
201000002282 venous insufficiency Diseases 0.000 claims description 5
ZCAPVKVQKGVVEP-UHFFFAOYSA-N 2,3-dibromo-5-fluoronaphthalene-1,4-dione Chemical compound O=C1C(Br)=C(Br)C(=O)C2=C1C=CC=C2F ZCAPVKVQKGVVEP-UHFFFAOYSA-N 0.000 claims description 4
TZJASHIDYNOMFL-UHFFFAOYSA-N 2,3-dibromo-5-methylnaphthalene-1,4-dione Chemical compound O=C1C(Br)=C(Br)C(=O)C2=C1C=CC=C2C TZJASHIDYNOMFL-UHFFFAOYSA-N 0.000 claims description 4
WCNZRLIEPPOFCH-UHFFFAOYSA-N 2,3-dibromo-6-fluoronaphthalene-1,4-dione Chemical compound O=C1C(Br)=C(Br)C(=O)C2=CC(F)=CC=C21 WCNZRLIEPPOFCH-UHFFFAOYSA-N 0.000 claims description 4
QMVLNNDZQQMMHT-UHFFFAOYSA-N 2-(furan-2-yl)-5-methoxybenzo[f][1,3]benzothiazole-4,9-dione Chemical compound N=1C=2C(=O)C=3C(OC)=CC=CC=3C(=O)C=2SC=1C1=CC=CO1 QMVLNNDZQQMMHT-UHFFFAOYSA-N 0.000 claims description 4
PTBHGQZZVAILEN-UHFFFAOYSA-N 3-amino-2-chloro-6-methylnaphthalene-1,4-dione Chemical compound O=C1C(Cl)=C(N)C(=O)C2=CC(C)=CC=C21 PTBHGQZZVAILEN-UHFFFAOYSA-N 0.000 claims description 4
DBDLTJRCKGCKSK-UHFFFAOYSA-N 5-methoxynaphthalene-1,4-dione Chemical compound O=C1C=CC(=O)C2=C1C=CC=C2OC DBDLTJRCKGCKSK-UHFFFAOYSA-N 0.000 claims description 4
230000007170 pathology Effects 0.000 claims description 4
230000035939 shock Effects 0.000 claims description 4
WODGMQAJBGQELR-UHFFFAOYSA-N 2-(1,3-thiazol-2-yl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C3=CC=CC=C3C(=O)C=2N=C1C1=NC=CS1 WODGMQAJBGQELR-UHFFFAOYSA-N 0.000 claims description 3
XUFYAZPAMNFIPW-UHFFFAOYSA-N 2-(2-fluorophenyl)-1h-benzo[f]benzimidazole-4,9-dione Chemical compound FC1=CC=CC=C1C1=NC(C(C2=CC=CC=C2C2=O)=O)=C2N1 XUFYAZPAMNFIPW-UHFFFAOYSA-N 0.000 claims description 3
XNADZOBJRIJMMY-UHFFFAOYSA-N 2-(2-fluorophenyl)benzo[f][1,3]benzoxazole-4,9-dione Chemical compound FC1=CC=CC=C1C1=NC(C(C2=CC=CC=C2C2=O)=O)=C2O1 XNADZOBJRIJMMY-UHFFFAOYSA-N 0.000 claims description 3
KVNGKHBBAJGPLK-UHFFFAOYSA-N 2-(3-methylphenyl)benzo[f][1,3]benzoxazole-4,9-dione Chemical compound CC1=CC=CC(C=2OC3=C(C(C4=CC=CC=C4C3=O)=O)N=2)=C1 KVNGKHBBAJGPLK-UHFFFAOYSA-N 0.000 claims description 3
QACAEHLFWZCANV-UHFFFAOYSA-N 2-(4-bromofuran-2-yl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound BrC1=COC(C=2SC3=C(C(C4=CC=CC=C4C3=O)=O)N=2)=C1 QACAEHLFWZCANV-UHFFFAOYSA-N 0.000 claims description 3
UOHJTGWIWLKOFH-UHFFFAOYSA-N 2-(5-aminofuran-2-yl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound O1C(N)=CC=C1C1=NC(C(C2=CC=CC=C2C2=O)=O)=C2S1 UOHJTGWIWLKOFH-UHFFFAOYSA-N 0.000 claims description 3
SIMPADCLDHQYQI-UHFFFAOYSA-N 2-(5-bromofuran-2-yl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound O1C(Br)=CC=C1C1=NC(C(C2=CC=CC=C2C2=O)=O)=C2S1 SIMPADCLDHQYQI-UHFFFAOYSA-N 0.000 claims description 3
DIRFZICDHCBSNE-UHFFFAOYSA-N 2-(5-chlorofuran-2-yl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound O1C(Cl)=CC=C1C1=NC(C(C2=CC=CC=C2C2=O)=O)=C2S1 DIRFZICDHCBSNE-UHFFFAOYSA-N 0.000 claims description 3
AWQDKXZMIPOUHG-UHFFFAOYSA-N 2-(5-nitrofuran-2-yl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound O1C([N+](=O)[O-])=CC=C1C1=NC(C(C2=CC=CC=C2C2=O)=O)=C2S1 AWQDKXZMIPOUHG-UHFFFAOYSA-N 0.000 claims description 3
PQKOTJDKHSLTLO-UHFFFAOYSA-N 2-(5-phenyl-1,3-oxazol-2-yl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C3=CC=CC=C3C(=O)C=2N=C1C(O1)=NC=C1C1=CC=CC=C1 PQKOTJDKHSLTLO-UHFFFAOYSA-N 0.000 claims description 3
UQKJPDYJFTVJOA-UHFFFAOYSA-N 2-(furan-2-yl)-8-methoxybenzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C=3C(OC)=CC=CC=3C(=O)C=2N=C1C1=CC=CO1 UQKJPDYJFTVJOA-UHFFFAOYSA-N 0.000 claims description 3
CTCDJSQYICTGPT-UHFFFAOYSA-N 2-amino-3-bromo-5-fluoronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(N)=C(Br)C(=O)C2=C1F CTCDJSQYICTGPT-UHFFFAOYSA-N 0.000 claims description 3
DEIOLVIXEQNANK-UHFFFAOYSA-N 2-amino-3-bromo-5-methylnaphthalene-1,4-dione Chemical compound O=C1C(N)=C(Br)C(=O)C2=C1C=CC=C2C DEIOLVIXEQNANK-UHFFFAOYSA-N 0.000 claims description 3
PPWXETUTFRZGNR-UHFFFAOYSA-N 2-pyridin-4-ylbenzo[f][1,3]benzothiazole-4,9-dione;sulfuric acid Chemical compound OS(O)(=O)=O.S1C=2C(=O)C3=CC=CC=C3C(=O)C=2N=C1C1=CC=NC=C1 PPWXETUTFRZGNR-UHFFFAOYSA-N 0.000 claims description 3
JISXAFDAZIGTGT-UHFFFAOYSA-N 2-thiophen-2-ylbenzo[f][1,3]benzoxazole-4,9-dione Chemical compound O1C=2C(=O)C3=CC=CC=C3C(=O)C=2N=C1C1=CC=CS1 JISXAFDAZIGTGT-UHFFFAOYSA-N 0.000 claims description 3
VBGCFJTVRSMYFJ-UHFFFAOYSA-N 7-methyl-2-(4-oxofuran-2-yl)-4h-benzo[f][1,3]benzothiazol-9-one Chemical compound S1C=2C(=O)C3=CC(C)=CC=C3CC=2N=C1C1=CC(=O)CO1 VBGCFJTVRSMYFJ-UHFFFAOYSA-N 0.000 claims description 3
QLPMNLPHWFASFB-UHFFFAOYSA-N 7-methyl-2-phenylbenzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C3=CC(C)=CC=C3C(=O)C=2N=C1C1=CC=CC=C1 QLPMNLPHWFASFB-UHFFFAOYSA-N 0.000 claims description 3
UFQQAIJDUDGRKQ-UHFFFAOYSA-N 8-hydroxy-2-phenylbenzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C=3C(O)=CC=CC=3C(=O)C=2N=C1C1=CC=CC=C1 UFQQAIJDUDGRKQ-UHFFFAOYSA-N 0.000 claims description 3
208000019695 Migraine disease Diseases 0.000 claims description 3
206010027599 migraine Diseases 0.000 claims description 3
SPTHAPOLVDKHEU-UHFFFAOYSA-N 2,3-dimethylbenzo[f]benzimidazole-4,9-dione;sulfuric acid Chemical compound OS(O)(=O)=O.C1=CC=C2C(=O)C(N=C(N3C)C)=C3C(=O)C2=C1 SPTHAPOLVDKHEU-UHFFFAOYSA-N 0.000 claims description 2
WBYCJQNVYQHORN-UHFFFAOYSA-N 2-(2,4-difluorophenyl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound FC1=CC(F)=CC=C1C1=NC(C(C2=CC=CC=C2C2=O)=O)=C2S1 WBYCJQNVYQHORN-UHFFFAOYSA-N 0.000 claims description 2
HWTVJTHJMSXSOF-UHFFFAOYSA-N 2-(2-chlorophenyl)benzo[f][1,3]benzoxazole-4,9-dione Chemical compound ClC1=CC=CC=C1C1=NC(C(C2=CC=CC=C2C2=O)=O)=C2O1 HWTVJTHJMSXSOF-UHFFFAOYSA-N 0.000 claims description 2
BWXOYLNSHSYDNQ-UHFFFAOYSA-N 2-(2-fluorophenyl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound FC1=CC=CC=C1C1=NC(C(C2=CC=CC=C2C2=O)=O)=C2S1 BWXOYLNSHSYDNQ-UHFFFAOYSA-N 0.000 claims description 2
XBQGMLKSFKIZCL-UHFFFAOYSA-N 2-(2-methylphenyl)benzo[f][1,3]benzoxazole-4,9-dione Chemical compound CC1=CC=CC=C1C1=NC(C(C2=CC=CC=C2C2=O)=O)=C2O1 XBQGMLKSFKIZCL-UHFFFAOYSA-N 0.000 claims description 2
UJVALBUTSNZOBZ-UHFFFAOYSA-N 2-(3-bromofuran-2-yl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound C1=COC(C=2SC3=C(C(C4=CC=CC=C4C3=O)=O)N=2)=C1Br UJVALBUTSNZOBZ-UHFFFAOYSA-N 0.000 claims description 2
KAWYXBAJUAUINZ-UHFFFAOYSA-N 2-(3-fluorophenyl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound FC1=CC=CC(C=2SC3=C(C(C4=CC=CC=C4C3=O)=O)N=2)=C1 KAWYXBAJUAUINZ-UHFFFAOYSA-N 0.000 claims description 2
WDBHOFNPFSGTHC-UHFFFAOYSA-N 2-(3-fluorophenyl)benzo[f][1,3]benzoxazole-4,9-dione Chemical compound FC1=CC=CC(C=2OC3=C(C(C4=CC=CC=C4C3=O)=O)N=2)=C1 WDBHOFNPFSGTHC-UHFFFAOYSA-N 0.000 claims description 2
YQJQMUCPWRWSLJ-UHFFFAOYSA-N 2-(4,5-dibromofuran-2-yl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound O1C(Br)=C(Br)C=C1C1=NC(C(C2=CC=CC=C2C2=O)=O)=C2S1 YQJQMUCPWRWSLJ-UHFFFAOYSA-N 0.000 claims description 2
WSIVCDGLAAOUAM-UHFFFAOYSA-N 2-(4-chlorophenyl)benzo[f][1,3]benzoxazole-4,9-dione Chemical compound C1=CC(Cl)=CC=C1C1=NC(C(C2=CC=CC=C2C2=O)=O)=C2O1 WSIVCDGLAAOUAM-UHFFFAOYSA-N 0.000 claims description 2
ZZXJDJRHXRPFCR-UHFFFAOYSA-N 2-(4-fluorophenyl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound C1=CC(F)=CC=C1C1=NC(C(C2=CC=CC=C2C2=O)=O)=C2S1 ZZXJDJRHXRPFCR-UHFFFAOYSA-N 0.000 claims description 2
ULJDFEYQOPCCPM-UHFFFAOYSA-N 2-(4-fluorophenyl)benzo[f][1,3]benzoxazole-4,9-dione Chemical compound C1=CC(F)=CC=C1C1=NC(C(C2=CC=CC=C2C2=O)=O)=C2O1 ULJDFEYQOPCCPM-UHFFFAOYSA-N 0.000 claims description 2
WEUDJJQFPFEFPO-UHFFFAOYSA-N 2-(4-methoxyphenyl)benzo[f][1,3]benzoxazole-4,9-dione Chemical compound C1=CC(OC)=CC=C1C1=NC(C(C2=CC=CC=C2C2=O)=O)=C2O1 WEUDJJQFPFEFPO-UHFFFAOYSA-N 0.000 claims description 2
NJPRVJMBTWGYAB-UHFFFAOYSA-N 2-(furan-2-yl)-6-methoxybenzo[f][1,3]benzothiazole-4,9-dione Chemical compound N=1C=2C(=O)C3=CC(OC)=CC=C3C(=O)C=2SC=1C1=CC=CO1 NJPRVJMBTWGYAB-UHFFFAOYSA-N 0.000 claims description 2
JTZQOZNCHKHLLN-UHFFFAOYSA-N 2-(furan-2-yl)-7-methoxybenzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C3=CC(OC)=CC=C3C(=O)C=2N=C1C1=CC=CO1 JTZQOZNCHKHLLN-UHFFFAOYSA-N 0.000 claims description 2
HCJYSVXDXDYSED-UHFFFAOYSA-N 2-(furan-3-yl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C3=CC=CC=C3C(=O)C=2N=C1C=1C=COC=1 HCJYSVXDXDYSED-UHFFFAOYSA-N 0.000 claims description 2
PZJJWOBITMYLFQ-UHFFFAOYSA-N 2-anilinobenzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C3=CC=CC=C3C(=O)C=2N=C1NC1=CC=CC=C1 PZJJWOBITMYLFQ-UHFFFAOYSA-N 0.000 claims description 2
WEOBMYUTPYXMRM-UHFFFAOYSA-N 2-pyridin-3-ylbenzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C3=CC=CC=C3C(=O)C=2N=C1C1=CC=CN=C1 WEOBMYUTPYXMRM-UHFFFAOYSA-N 0.000 claims description 2
ZGHCUFXULYADMS-UHFFFAOYSA-N 2-thiophen-2-ylbenzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C3=CC=CC=C3C(=O)C=2N=C1C1=CC=CS1 ZGHCUFXULYADMS-UHFFFAOYSA-N 0.000 claims description 2
FTDCOVZWOANATD-UHFFFAOYSA-N 2-thiophen-3-ylbenzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C3=CC=CC=C3C(=O)C=2N=C1C=1C=CSC=1 FTDCOVZWOANATD-UHFFFAOYSA-N 0.000 claims description 2
FMYCGBHYGJLPJE-UHFFFAOYSA-N 3-amino-2-bromo-5-fluoronaphthalene-1,4-dione Chemical compound C1=CC(F)=C2C(=O)C(N)=C(Br)C(=O)C2=C1 FMYCGBHYGJLPJE-UHFFFAOYSA-N 0.000 claims description 2
GAJHIHMKTAOXSX-UHFFFAOYSA-N 3-amino-2-bromo-5-methylnaphthalene-1,4-dione Chemical compound O=C1C(Br)=C(N)C(=O)C2=C1C=CC=C2C GAJHIHMKTAOXSX-UHFFFAOYSA-N 0.000 claims description 2
XDFMBCOYRSZPPK-UHFFFAOYSA-N 5-fluoro-2-(furan-2-yl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound N=1C=2C(=O)C=3C(F)=CC=CC=3C(=O)C=2SC=1C1=CC=CO1 XDFMBCOYRSZPPK-UHFFFAOYSA-N 0.000 claims description 2
QWNVAIGNJXBNLZ-UHFFFAOYSA-N 5-methyl-2-(4-oxofuran-2-yl)-4h-benzo[f][1,3]benzothiazol-9-one Chemical compound N=1C=2CC=3C(C)=CC=CC=3C(=O)C=2SC=1C1=CC(=O)CO1 QWNVAIGNJXBNLZ-UHFFFAOYSA-N 0.000 claims description 2
ZLDIIMNECGPNHE-UHFFFAOYSA-N 5-methyl-2-phenylbenzo[f][1,3]benzothiazole-4,9-dione Chemical compound N=1C=2C(=O)C=3C(C)=CC=CC=3C(=O)C=2SC=1C1=CC=CC=C1 ZLDIIMNECGPNHE-UHFFFAOYSA-N 0.000 claims description 2
SAKVALIVNPPJEB-UHFFFAOYSA-N 6-fluoro-2-(4-fluorophenyl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound C1=CC(F)=CC=C1C1=NC(C(C2=CC(F)=CC=C2C2=O)=O)=C2S1 SAKVALIVNPPJEB-UHFFFAOYSA-N 0.000 claims description 2
RDCXUSTWGGGHPO-UHFFFAOYSA-N 6-fluoro-2-(4-methylphenyl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound C1=CC(C)=CC=C1C1=NC(C(C2=CC(F)=CC=C2C2=O)=O)=C2S1 RDCXUSTWGGGHPO-UHFFFAOYSA-N 0.000 claims description 2
GMGCRPBPCLMUIC-UHFFFAOYSA-N 6-fluoro-2-(5-methylfuran-2-yl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound O1C(C)=CC=C1C1=NC(C(C2=CC(F)=CC=C2C2=O)=O)=C2S1 GMGCRPBPCLMUIC-UHFFFAOYSA-N 0.000 claims description 2
UTTAXUHMYINTMX-UHFFFAOYSA-N 6-fluoro-2-(furan-2-yl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound N=1C=2C(=O)C3=CC(F)=CC=C3C(=O)C=2SC=1C1=CC=CO1 UTTAXUHMYINTMX-UHFFFAOYSA-N 0.000 claims description 2
LSGOCDXRYJHIEQ-UHFFFAOYSA-N 6-fluoro-2-phenylbenzo[f][1,3]benzothiazole-4,9-dione Chemical compound N=1C=2C(=O)C3=CC(F)=CC=C3C(=O)C=2SC=1C1=CC=CC=C1 LSGOCDXRYJHIEQ-UHFFFAOYSA-N 0.000 claims description 2
ZDLKOTRSOCOFCP-UHFFFAOYSA-N 6-methoxy-2-phenylbenzo[f][1,3]benzothiazole-4,9-dione Chemical compound N=1C=2C(=O)C3=CC(OC)=CC=C3C(=O)C=2SC=1C1=CC=CC=C1 ZDLKOTRSOCOFCP-UHFFFAOYSA-N 0.000 claims description 2
OEURFZARVCAAPN-UHFFFAOYSA-N 7-chloro-2-(furan-2-yl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C3=CC(Cl)=CC=C3C(=O)C=2N=C1C1=CC=CO1 OEURFZARVCAAPN-UHFFFAOYSA-N 0.000 claims description 2
HNZBUGJHGYBFOS-UHFFFAOYSA-N 7-fluoro-2-(4-methylphenyl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound C1=CC(C)=CC=C1C1=NC(C(C2=CC=C(F)C=C2C2=O)=O)=C2S1 HNZBUGJHGYBFOS-UHFFFAOYSA-N 0.000 claims description 2
YYWKHRFJVRDNCF-UHFFFAOYSA-N 7-fluoro-2-(5-methylfuran-2-yl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound O1C(C)=CC=C1C1=NC(C(C2=CC=C(F)C=C2C2=O)=O)=C2S1 YYWKHRFJVRDNCF-UHFFFAOYSA-N 0.000 claims description 2
RICGFIYGULTJDH-UHFFFAOYSA-N 7-fluoro-2-(furan-2-yl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C3=CC(F)=CC=C3C(=O)C=2N=C1C1=CC=CO1 RICGFIYGULTJDH-UHFFFAOYSA-N 0.000 claims description 2
IEDQSQUWNPZGKG-UHFFFAOYSA-N 7-fluoro-2-phenylbenzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C3=CC(F)=CC=C3C(=O)C=2N=C1C1=CC=CC=C1 IEDQSQUWNPZGKG-UHFFFAOYSA-N 0.000 claims description 2
MBSQDZBRDUZPEL-UHFFFAOYSA-N 8-fluoro-2-(furan-2-yl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C=3C(F)=CC=CC=3C(=O)C=2N=C1C1=CC=CO1 MBSQDZBRDUZPEL-UHFFFAOYSA-N 0.000 claims description 2
GZMWIVFESHCPOY-UHFFFAOYSA-N 8-methyl-2-phenylbenzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C=3C(C)=CC=CC=3C(=O)C=2N=C1C1=CC=CC=C1 GZMWIVFESHCPOY-UHFFFAOYSA-N 0.000 claims description 2
206010061218 Inflammation Diseases 0.000 claims description 2
230000002526 effect on cardiovascular system Effects 0.000 claims description 2
230000004054 inflammatory process Effects 0.000 claims description 2
150000002926 oxygen Chemical group 0.000 claims description 2
239000011593 sulfur Substances 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
125000004429 atom Chemical group 0.000 claims 2
VYIHPRSTNSUTDF-UHFFFAOYSA-N 2-(4,5-dimethylfuran-2-yl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound O1C(C)=C(C)C=C1C1=NC(C(C2=CC=CC=C2C2=O)=O)=C2S1 VYIHPRSTNSUTDF-UHFFFAOYSA-N 0.000 claims 1
NHAYOCHSPVTTII-UHFFFAOYSA-N 2-(5-methylfuran-2-yl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound O1C(C)=CC=C1C1=NC(C(C2=CC=CC=C2C2=O)=O)=C2S1 NHAYOCHSPVTTII-UHFFFAOYSA-N 0.000 claims 1
XTTVXBZQXSTPSO-UHFFFAOYSA-N 2-(furan-2-yl)-5-hydroxybenzo[f][1,3]benzothiazole-4,9-dione Chemical compound N=1C=2C(=O)C=3C(O)=CC=CC=3C(=O)C=2SC=1C1=CC=CO1 XTTVXBZQXSTPSO-UHFFFAOYSA-N 0.000 claims 1
WAGSLSVGWQJTKQ-UHFFFAOYSA-N 2-(furan-2-yl)-8-hydroxybenzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C=3C(O)=CC=CC=3C(=O)C=2N=C1C1=CC=CO1 WAGSLSVGWQJTKQ-UHFFFAOYSA-N 0.000 claims 1
JQRBBNORAFCWLO-UHFFFAOYSA-N 2-pyrrol-1-ylbenzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C3=CC=CC=C3C(=O)C=2N=C1N1C=CC=C1 JQRBBNORAFCWLO-UHFFFAOYSA-N 0.000 claims 1
FRGLVKLVMQFUBQ-UHFFFAOYSA-N 6-chloro-2-(furan-2-yl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound N=1C=2C(=O)C3=CC(Cl)=CC=C3C(=O)C=2SC=1C1=CC=CO1 FRGLVKLVMQFUBQ-UHFFFAOYSA-N 0.000 claims 1
NQZZQASWBVPEFO-UHFFFAOYSA-N 6-methyl-2-phenylbenzo[f][1,3]benzothiazole-4,9-dione Chemical compound N=1C=2C(=O)C3=CC(C)=CC=C3C(=O)C=2SC=1C1=CC=CC=C1 NQZZQASWBVPEFO-UHFFFAOYSA-N 0.000 claims 1
DSGKYGXTHXHGOP-UHFFFAOYSA-N 7-fluoro-2-(4-fluorophenyl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound C1=CC(F)=CC=C1C1=NC(C(C2=CC=C(F)C=C2C2=O)=O)=C2S1 DSGKYGXTHXHGOP-UHFFFAOYSA-N 0.000 claims 1
MODVUQQUKVJFTA-UHFFFAOYSA-N 8-methyl-2-(4-oxofuran-2-yl)-4h-benzo[f][1,3]benzothiazol-9-one Chemical compound S1C=2C(=O)C=3C(C)=CC=CC=3CC=2N=C1C1=CC(=O)CO1 MODVUQQUKVJFTA-UHFFFAOYSA-N 0.000 claims 1
CMWJBYIVCQDUFK-UHFFFAOYSA-N [5-(4,9-dioxobenzo[f][1,3]benzothiazol-2-yl)-4-methylfuran-2-yl] acetate Chemical compound O1C(OC(=O)C)=CC(C)=C1C1=NC(C(C2=CC=CC=C2C2=O)=O)=C2S1 CMWJBYIVCQDUFK-UHFFFAOYSA-N 0.000 claims 1
230000004075 alteration Effects 0.000 claims 1
239000005667 attractant Substances 0.000 claims 1
230000031902 chemoattractant activity Effects 0.000 claims 1
125000004430 oxygen atom Chemical group O* 0.000 abstract description 4
239000005864 Sulphur Substances 0.000 abstract 1
230000007812 deficiency Effects 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 483
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 210
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 142
239000000460 chlorine Substances 0.000 description 134
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 126
229910052801 chlorine Inorganic materials 0.000 description 109
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 105
239000000243 solution Substances 0.000 description 105
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 85
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 85
238000005481 NMR spectroscopy Methods 0.000 description 69
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 65
239000013078 crystal Substances 0.000 description 61
239000003480 eluent Substances 0.000 description 60
239000000047 product Substances 0.000 description 59
239000000377 silicon dioxide Substances 0.000 description 58
239000000203 mixture Substances 0.000 description 53
238000005160 1H NMR spectroscopy Methods 0.000 description 52
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 43
239000002244 precipitate Substances 0.000 description 43
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
238000001704 evaporation Methods 0.000 description 37
230000008020 evaporation Effects 0.000 description 37
229960000583 acetic acid Drugs 0.000 description 33
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 31
239000002904 solvent Substances 0.000 description 31
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
239000011541 reaction mixture Substances 0.000 description 28
-1 C1-C5 alkyl radical Chemical class 0.000 description 26
YMWUJEATGCHHMB-DICFDUPASA-N dichloromethane-d2 Chemical compound [2H]C([2H])(Cl)Cl YMWUJEATGCHHMB-DICFDUPASA-N 0.000 description 26
239000000725 suspension Substances 0.000 description 26
239000012429 reaction media Substances 0.000 description 25
239000007787 solid Substances 0.000 description 24
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 23
241001465754 Metazoa Species 0.000 description 23
241000700159 Rattus Species 0.000 description 23
ZGHLCBJZQLNUAZ-UHFFFAOYSA-N sodium sulfide nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[S-2] ZGHLCBJZQLNUAZ-UHFFFAOYSA-N 0.000 description 23
229910052799 carbon Inorganic materials 0.000 description 22
238000010992 reflux Methods 0.000 description 20
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 19
239000001110 calcium chloride Substances 0.000 description 19
229910001628 calcium chloride Inorganic materials 0.000 description 19
235000011148 calcium chloride Nutrition 0.000 description 19
239000012074 organic phase Substances 0.000 description 16
OBLNWSCLAYSJJR-UHFFFAOYSA-N Quinoclamin Chemical compound C1=CC=C2C(=O)C(N)=C(Cl)C(=O)C2=C1 OBLNWSCLAYSJJR-UHFFFAOYSA-N 0.000 description 15
230000003750 conditioning effect Effects 0.000 description 15
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
239000012362 glacial acetic acid Substances 0.000 description 14
239000011521 glass Substances 0.000 description 14
238000003756 stirring Methods 0.000 description 14
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 13
239000007864 aqueous solution Substances 0.000 description 13
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
238000001816 cooling Methods 0.000 description 12
HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 12
238000002347 injection Methods 0.000 description 12
239000007924 injection Substances 0.000 description 12
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 10
HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 10
230000000694 effects Effects 0.000 description 10
229910052731 fluorine Inorganic materials 0.000 description 10
239000000843 powder Substances 0.000 description 10
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 9
239000000741 silica gel Substances 0.000 description 9
229910002027 silica gel Inorganic materials 0.000 description 9
241000283973 Oryctolagus cuniculus Species 0.000 description 8
239000002253 acid Substances 0.000 description 8
238000004042 decolorization Methods 0.000 description 8
238000000034 method Methods 0.000 description 8
230000002792 vascular Effects 0.000 description 8
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 7
229910052786 argon Inorganic materials 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
239000012043 crude product Substances 0.000 description 7
239000000706 filtrate Substances 0.000 description 7
238000001914 filtration Methods 0.000 description 7
239000000543 intermediate Substances 0.000 description 7
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 7
238000001953 recrystallisation Methods 0.000 description 7
239000012265 solid product Substances 0.000 description 7
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
229910021529 ammonia Inorganic materials 0.000 description 6
HJLDPBXWNCCXGM-UHFFFAOYSA-N benzo[f][1,3]benzothiazole Chemical compound C1=CC=C2C=C(SC=N3)C3=CC2=C1 HJLDPBXWNCCXGM-UHFFFAOYSA-N 0.000 description 6
230000001595 contractor effect Effects 0.000 description 6
239000012153 distilled water Substances 0.000 description 6
238000003818 flash chromatography Methods 0.000 description 6
230000001965 increasing effect Effects 0.000 description 6
229910052943 magnesium sulfate Inorganic materials 0.000 description 6
235000019341 magnesium sulphate Nutrition 0.000 description 6
230000000144 pharmacologic effect Effects 0.000 description 6
150000003254 radicals Chemical class 0.000 description 6
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 5
239000012300 argon atmosphere Substances 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
230000002999 depolarising effect Effects 0.000 description 5
229960001340 histamine Drugs 0.000 description 5
230000006698 induction Effects 0.000 description 5
QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
FRASJONUBLZVQX-UHFFFAOYSA-N 1,4-naphthoquinone Chemical compound C1=CC=C2C(=O)C=CC(=O)C2=C1 FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 description 4
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 4
YSARSOPNCPYXJI-UHFFFAOYSA-N benzo[f][1,3]benzothiazole-4,9-dione Chemical class O=C1C2=CC=CC=C2C(=O)C2=C1SC=N2 YSARSOPNCPYXJI-UHFFFAOYSA-N 0.000 description 4
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
229910052794 bromium Inorganic materials 0.000 description 4
230000005587 bubbling Effects 0.000 description 4
229940089960 chloroacetate Drugs 0.000 description 4
230000008602 contraction Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
239000002158 endotoxin Substances 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
238000001990 intravenous administration Methods 0.000 description 4
230000007935 neutral effect Effects 0.000 description 4
208000008423 pleurisy Diseases 0.000 description 4
239000011734 sodium Substances 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
210000003462 vein Anatomy 0.000 description 4
DSABGXKNIWFVGX-UHFFFAOYSA-N 2,3-dimethylbenzo[f]benzimidazole-4,9-dione Chemical compound C1=CC=C2C(=O)C(N=C(N3C)C)=C3C(=O)C2=C1 DSABGXKNIWFVGX-UHFFFAOYSA-N 0.000 description 3
VJKZUTFFMNSTTD-UHFFFAOYSA-N 2-(furan-2-yl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C3=CC=CC=C3C(=O)C=2N=C1C1=CC=CO1 VJKZUTFFMNSTTD-UHFFFAOYSA-N 0.000 description 3
125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 3
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
206010015866 Extravasation Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
206010037549 Purpura Diseases 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
210000001367 artery Anatomy 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
239000011449 brick Substances 0.000 description 3
239000002775 capsule Substances 0.000 description 3
235000010418 carrageenan Nutrition 0.000 description 3
229920001525 carrageenan Polymers 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
230000008859 change Effects 0.000 description 3
238000002845 discoloration Methods 0.000 description 3
238000001035 drying Methods 0.000 description 3
230000036251 extravasation Effects 0.000 description 3
238000010438 heat treatment Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
229920006008 lipopolysaccharide Polymers 0.000 description 3
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 3
229910052753 mercury Inorganic materials 0.000 description 3
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 3
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 3
206010034754 petechiae Diseases 0.000 description 3
210000003752 saphenous vein Anatomy 0.000 description 3
238000000926 separation method Methods 0.000 description 3
235000017557 sodium bicarbonate Nutrition 0.000 description 3
229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
SVPKNMBRVBMTLB-UHFFFAOYSA-N 2,3-dichloronaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(Cl)=C(Cl)C(=O)C2=C1 SVPKNMBRVBMTLB-UHFFFAOYSA-N 0.000 description 2
UPUWMQZUXFAUCJ-UHFFFAOYSA-N 2,5-dihydro-1,2-thiazole Chemical compound C1SNC=C1 UPUWMQZUXFAUCJ-UHFFFAOYSA-N 0.000 description 2
UHVIJLZSYHZCRS-UHFFFAOYSA-N 2-[5-(hydroxymethyl)furan-2-yl]benzo[f][1,3]benzothiazole-4,9-dione Chemical compound O1C(CO)=CC=C1C1=NC(C(C2=CC=CC=C2C2=O)=O)=C2S1 UHVIJLZSYHZCRS-UHFFFAOYSA-N 0.000 description 2
WHFSKJQUVSVCCA-UHFFFAOYSA-N 2-amino-3-bromo-6-methoxynaphthalene-1,4-dione Chemical compound O=C1C(N)=C(Br)C(=O)C2=CC(OC)=CC=C21 WHFSKJQUVSVCCA-UHFFFAOYSA-N 0.000 description 2
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 2
QALUABPVLVEXIB-UHFFFAOYSA-N 2-pyridin-4-ylbenzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C3=CC=CC=C3C(=O)C=2N=C1C1=CC=NC=C1 QALUABPVLVEXIB-UHFFFAOYSA-N 0.000 description 2
KSAVZSUPQGDMRC-UHFFFAOYSA-N 3-bromofuran-2-carbaldehyde Chemical compound BrC=1C=COC=1C=O KSAVZSUPQGDMRC-UHFFFAOYSA-N 0.000 description 2
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 2
OUDFNZMQXZILJD-UHFFFAOYSA-N 5-methyl-2-furaldehyde Chemical compound CC1=CC=C(C=O)O1 OUDFNZMQXZILJD-UHFFFAOYSA-N 0.000 description 2
GJRAYWVAZQGENN-UHFFFAOYSA-N 5-phenyl-1,3-oxazole-2-carbaldehyde Chemical compound O1C(C=O)=NC=C1C1=CC=CC=C1 GJRAYWVAZQGENN-UHFFFAOYSA-N 0.000 description 2
CRWQOXNARPFUOY-UHFFFAOYSA-N 6-methyl-2-(4-oxofuran-2-yl)-4h-benzo[f][1,3]benzothiazol-9-one Chemical compound N=1C=2CC3=CC(C)=CC=C3C(=O)C=2SC=1C1=CC(=O)CO1 CRWQOXNARPFUOY-UHFFFAOYSA-N 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
241000699800 Cricetinae Species 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
206010012735 Diarrhoea Diseases 0.000 description 2
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
208000010496 Heart Arrest Diseases 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000004040 coloring Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
230000008021 deposition Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
210000000416 exudates and transudate Anatomy 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000005259 measurement Methods 0.000 description 2
NUOZWAFGWDBXKM-UHFFFAOYSA-N n-[5-(4,9-dioxobenzo[f][1,3]benzothiazol-2-yl)furan-2-yl]acetamide Chemical compound O1C(NC(=O)C)=CC=C1C1=NC(C(C2=CC=CC=C2C2=O)=O)=C2S1 NUOZWAFGWDBXKM-UHFFFAOYSA-N 0.000 description 2
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
239000002674 ointment Substances 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
FXLOVSHXALFLKQ-UHFFFAOYSA-N p-tolualdehyde Chemical compound CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
238000012746 preparative thin layer chromatography Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
239000012047 saturated solution Substances 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 2
229940079101 sodium sulfide Drugs 0.000 description 2
229910052979 sodium sulfide Inorganic materials 0.000 description 2
229940048181 sodium sulfide nonahydrate Drugs 0.000 description 2
WMDLZMCDBSJMTM-UHFFFAOYSA-M sodium;sulfanide;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[SH-] WMDLZMCDBSJMTM-UHFFFAOYSA-M 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
239000003826 tablet Substances 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
238000010865 video microscopy Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
QAVITTVTXPZTSE-UHFFFAOYSA-N (5-formylfuran-2-yl)methyl acetate Chemical compound CC(=O)OCC1=CC=C(C=O)O1 QAVITTVTXPZTSE-UHFFFAOYSA-N 0.000 description 1
WUUUDNOHBDZGIV-UHFFFAOYSA-N (5-formylfuran-3-yl)methyl acetate Chemical compound CC(=O)OCC1=COC(C=O)=C1 WUUUDNOHBDZGIV-UHFFFAOYSA-N 0.000 description 1
KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
ZGTFNNUASMWGTM-UHFFFAOYSA-N 1,3-thiazole-2-carbaldehyde Chemical compound O=CC1=NC=CS1 ZGTFNNUASMWGTM-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
ABVGDXLCJRFCOD-UHFFFAOYSA-N 1h-benzo[f]benzimidazole-4,9-dione Chemical group O=C1C2=CC=CC=C2C(=O)C2=C1NC=N2 ABVGDXLCJRFCOD-UHFFFAOYSA-N 0.000 description 1
YGFBBXYYCLHOOW-UHFFFAOYSA-N 2,3-diaminonaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(N)=C(N)C(=O)C2=C1 YGFBBXYYCLHOOW-UHFFFAOYSA-N 0.000 description 1
PSMABVOYZJWFBV-UHFFFAOYSA-N 2,3-dibromonaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(Br)=C(Br)C(=O)C2=C1 PSMABVOYZJWFBV-UHFFFAOYSA-N 0.000 description 1
WCGPCBACLBHDCI-UHFFFAOYSA-N 2,4-difluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C(F)=C1 WCGPCBACLBHDCI-UHFFFAOYSA-N 0.000 description 1
GFISDBXSWQMOND-UHFFFAOYSA-N 2,5-dimethoxyoxolane Chemical compound COC1CCC(OC)O1 GFISDBXSWQMOND-UHFFFAOYSA-N 0.000 description 1
WMOVYMNVOWZNQD-UHFFFAOYSA-N 2-(1h-pyrrol-2-yl)benzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C3=CC=CC=C3C(=O)C=2N=C1C1=CC=CN1 WMOVYMNVOWZNQD-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
HECAAMUPHUFFOR-UHFFFAOYSA-N 2-amino-3,6-dichloronaphthalene-1,4-dione Chemical compound ClC1=CC=C2C(=O)C(N)=C(Cl)C(=O)C2=C1 HECAAMUPHUFFOR-UHFFFAOYSA-N 0.000 description 1
VBNXRWYRGFVVJF-UHFFFAOYSA-N 2-amino-3-bromo-5-fluoronaphthalene-1,4-dione 3-amino-2-bromo-5-fluoronaphthalene-1,4-dione Chemical compound NC=1C(C2=C(C=CC=C2C(C1Br)=O)F)=O.NC=1C(C2=CC=CC(=C2C(C1Br)=O)F)=O VBNXRWYRGFVVJF-UHFFFAOYSA-N 0.000 description 1
WGMUFYXEOGTTIC-UHFFFAOYSA-N 2-amino-3-bromo-6-methylnaphthalene-1,4-dione Chemical compound O=C1C(N)=C(Br)C(=O)C2=CC(C)=CC=C21 WGMUFYXEOGTTIC-UHFFFAOYSA-N 0.000 description 1
KOWUSQUHRUZOIH-UHFFFAOYSA-N 2-amino-3-sulfanylnaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(N)=C(S)C(=O)C2=C1 KOWUSQUHRUZOIH-UHFFFAOYSA-N 0.000 description 1
FDQQOCSYNXLLQS-UHFFFAOYSA-N 2-bromo-5-methoxynaphthalene-1,4-dione Chemical compound O=C1C(Br)=CC(=O)C2=C1C=CC=C2OC FDQQOCSYNXLLQS-UHFFFAOYSA-N 0.000 description 1
CCTJHVLTAJTPBV-UHFFFAOYSA-N 2-chloro-1,4-naphthoquinone Chemical compound C1=CC=C2C(=O)C(Cl)=CC(=O)C2=C1 CCTJHVLTAJTPBV-UHFFFAOYSA-N 0.000 description 1
YGLUWGGETBTCQG-UHFFFAOYSA-N 2-chloro-7-methylnaphthalene-1,4-dione Chemical compound O=C1C=C(Cl)C(=O)C2=CC(C)=CC=C21 YGLUWGGETBTCQG-UHFFFAOYSA-N 0.000 description 1
VNQHYBJNARAOKH-UHFFFAOYSA-N 2-chlorobenzo[f][1,3]benzothiazole-4,9-dione Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1SC(Cl)=N2 VNQHYBJNARAOKH-UHFFFAOYSA-N 0.000 description 1
ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 1
RAAGZOYMEQDCTD-UHFFFAOYSA-N 2-fluorobenzoyl chloride Chemical compound FC1=CC=CC=C1C(Cl)=O RAAGZOYMEQDCTD-UHFFFAOYSA-N 0.000 description 1
XGECDKOYGJRJEW-UHFFFAOYSA-N 2-methyl-3-phenylbenzo[f]benzimidazole-4,9-dione;sulfuric acid Chemical compound OS(O)(=O)=O.CC1=NC(C(C2=CC=CC=C2C2=O)=O)=C2N1C1=CC=CC=C1 XGECDKOYGJRJEW-UHFFFAOYSA-N 0.000 description 1
239000001431 2-methylbenzaldehyde Substances 0.000 description 1
VEDVLCBGJDVXTE-UHFFFAOYSA-N 2-methylbenzo[f][1,3]benzothiazole Chemical compound C1=CC=C2C=C(SC(C)=N3)C3=CC2=C1 VEDVLCBGJDVXTE-UHFFFAOYSA-N 0.000 description 1
SMADFTNSMNPBLG-UHFFFAOYSA-N 2-methylbenzo[f][1,3]benzothiazole-4,9-dione Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1SC(C)=N2 SMADFTNSMNPBLG-UHFFFAOYSA-N 0.000 description 1
GPZXFICWCMCQPF-UHFFFAOYSA-N 2-methylbenzoyl chloride Chemical compound CC1=CC=CC=C1C(Cl)=O GPZXFICWCMCQPF-UHFFFAOYSA-N 0.000 description 1
NHSOUBXHXGUPLL-UHFFFAOYSA-N 2-phenyl-1h-benzo[f]benzimidazole-4,9-dione Chemical compound N1C=2C(=O)C3=CC=CC=C3C(=O)C=2N=C1C1=CC=CC=C1 NHSOUBXHXGUPLL-UHFFFAOYSA-N 0.000 description 1
YJHSQTCHSGKFDB-UHFFFAOYSA-N 2-phenylbenzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C3=CC=CC=C3C(=O)C=2N=C1C1=CC=CC=C1 YJHSQTCHSGKFDB-UHFFFAOYSA-N 0.000 description 1
CMYQQADDUUDCCA-UHFFFAOYSA-N 2-phenylbenzo[f][1,3]benzoxazole-4,9-dione Chemical compound O1C=2C(=O)C3=CC=CC=C3C(=O)C=2N=C1C1=CC=CC=C1 CMYQQADDUUDCCA-UHFFFAOYSA-N 0.000 description 1
MZILMHPXACEFDJ-UHFFFAOYSA-N 2-pyridin-2-ylbenzo[f][1,3]benzothiazole-4,9-dione Chemical compound S1C=2C(=O)C3=CC=CC=C3C(=O)C=2N=C1C1=CC=CC=N1 MZILMHPXACEFDJ-UHFFFAOYSA-N 0.000 description 1
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
PNPYZAVSFRQRTR-UHFFFAOYSA-N 3-amino-2,6-dichloronaphthalene-1,4-dione Chemical compound C1=C(Cl)C=C2C(=O)C(N)=C(Cl)C(=O)C2=C1 PNPYZAVSFRQRTR-UHFFFAOYSA-N 0.000 description 1
IRVZIWWLRROHGJ-UHFFFAOYSA-N 3-amino-2-bromo-6-methoxynaphthalene-1,4-dione Chemical compound O=C1C(Br)=C(N)C(=O)C2=CC(OC)=CC=C21 IRVZIWWLRROHGJ-UHFFFAOYSA-N 0.000 description 1
PIKNVEVCWAAOMJ-UHFFFAOYSA-N 3-fluorobenzaldehyde Chemical compound FC1=CC=CC(C=O)=C1 PIKNVEVCWAAOMJ-UHFFFAOYSA-N 0.000 description 1
SYVNVEGIRVXRQH-UHFFFAOYSA-N 3-fluorobenzoyl chloride Chemical compound FC1=CC=CC(C(Cl)=O)=C1 SYVNVEGIRVXRQH-UHFFFAOYSA-N 0.000 description 1
RBIGKSZIQCTIJF-UHFFFAOYSA-N 3-formylthiophene Chemical compound O=CC=1C=CSC=1 RBIGKSZIQCTIJF-UHFFFAOYSA-N 0.000 description 1
YHOYYHYBFSYOSQ-UHFFFAOYSA-N 3-methylbenzoyl chloride Chemical compound CC1=CC=CC(C(Cl)=O)=C1 YHOYYHYBFSYOSQ-UHFFFAOYSA-N 0.000 description 1
JPTPEPVCVXGNJM-UHFFFAOYSA-N 4,5-dimethylfuran-2-carbaldehyde Chemical compound CC=1C=C(C=O)OC=1C JPTPEPVCVXGNJM-UHFFFAOYSA-N 0.000 description 1
MRGBBKQOSUHKPF-UHFFFAOYSA-N 4-bromofuran-2-carbaldehyde Chemical compound BrC1=COC(C=O)=C1 MRGBBKQOSUHKPF-UHFFFAOYSA-N 0.000 description 1
RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 1
AIVWISHCJSZPPP-UHFFFAOYSA-N 5-fluoronaphthalene-1,4-dione Chemical compound O=C1C=CC(=O)C2=C1C=CC=C2F AIVWISHCJSZPPP-UHFFFAOYSA-N 0.000 description 1
HVEQLLXOVCUBPR-UHFFFAOYSA-N 5-methylnaphthalene-1,4-dione Chemical compound O=C1C=CC(=O)C2=C1C=CC=C2C HVEQLLXOVCUBPR-UHFFFAOYSA-N 0.000 description 1
VLPUCMCQQFGFDF-UHFFFAOYSA-N 6-fluoronaphthalene-1,4-dione Chemical compound O=C1C=CC(=O)C2=CC(F)=CC=C21 VLPUCMCQQFGFDF-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
KZUJFCNXWFUVOR-UHFFFAOYSA-N 7-fluoronaphthalene-1,2-dione Chemical compound C1=CC(=O)C(=O)C2=CC(F)=CC=C21 KZUJFCNXWFUVOR-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
KAMACJHGHWOVBU-UHFFFAOYSA-N BrC=1C=C(OC1Br)C=1SC2=C(N1)C(C=1C=CC=CC1C2=O)=O.BrC2=CC=C(O2)C=2SC1=C(N2)C(C=2C=CC=CC2C1=O)=O Chemical compound BrC=1C=C(OC1Br)C=1SC2=C(N1)C(C=1C=CC=CC1C2=O)=O.BrC2=CC=C(O2)C=2SC1=C(N2)C(C=2C=CC=CC2C1=O)=O KAMACJHGHWOVBU-UHFFFAOYSA-N 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
238000006418 Brown reaction Methods 0.000 description 1
241000195940 Bryophyta Species 0.000 description 1
ZAYYTALGTYSVEI-UHFFFAOYSA-N C1(C=CC(C2=CC=CC=C12)=O)=O.[Cl] Chemical compound C1(C=CC(C2=CC=CC=C12)=O)=O.[Cl] ZAYYTALGTYSVEI-UHFFFAOYSA-N 0.000 description 1
COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
MLYACXBPZNWSSY-UHFFFAOYSA-N COC1=CC=CC2=CC3=C(C=C21)N=C(S3)C4=CC=CC=C4 Chemical compound COC1=CC=CC2=CC3=C(C=C21)N=C(S3)C4=CC=CC=C4 MLYACXBPZNWSSY-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
206010008796 Chromaturia Diseases 0.000 description 1
244000060011 Cocos nucifera Species 0.000 description 1
235000013162 Cocos nucifera Nutrition 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
240000001879 Digitalis lutea Species 0.000 description 1
241001269524 Dura Species 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
206010015548 Euthanasia Diseases 0.000 description 1
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
206010049976 Impatience Diseases 0.000 description 1
206010021639 Incontinence Diseases 0.000 description 1
239000007836 KH2PO4 Substances 0.000 description 1
102100035792 Kininogen-1 Human genes 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
XREBKKLUBSOKMI-UHFFFAOYSA-N NC=1C(C2=C(C=CC=C2C(C1Br)=O)C)=O.NC=1C(C2=CC=CC(=C2C(C1Br)=O)C)=O Chemical compound NC=1C(C2=C(C=CC=C2C(C1Br)=O)C)=O.NC=1C(C2=CC=CC(=C2C(C1Br)=O)C)=O XREBKKLUBSOKMI-UHFFFAOYSA-N 0.000 description 1
229930192627 Naphthoquinone Natural products 0.000 description 1
GIVHTHGZSFPTKB-UHFFFAOYSA-N O=C1C=2C=CC=C(C2C(C2=C1N=C(S2)C=2OC=CC2)=O)F.O=C2C=1C(=CC=CC1C(C1=C2N=C(S1)C=1OC=CC1)=O)F Chemical compound O=C1C=2C=CC=C(C2C(C2=C1N=C(S2)C=2OC=CC2)=O)F.O=C2C=1C(=CC=CC1C(C1=C2N=C(S1)C=1OC=CC1)=O)F GIVHTHGZSFPTKB-UHFFFAOYSA-N 0.000 description 1
VMCGCJPVDREMPB-UHFFFAOYSA-N O=C1C=2C=CC=CC2C(C2=C1N=C(S2)C=2OC(=CC2)[N+](=O)[O-])=O.BrC=2C=C(OC2)C=2SC1=C(N2)C(C=2C=CC=CC2C1=O)=O.S1C=NC=C1 Chemical compound O=C1C=2C=CC=CC2C(C2=C1N=C(S2)C=2OC(=CC2)[N+](=O)[O-])=O.BrC=2C=C(OC2)C=2SC1=C(N2)C(C=2C=CC=CC2C1=O)=O.S1C=NC=C1 VMCGCJPVDREMPB-UHFFFAOYSA-N 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000287531 Psittacidae Species 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
206010038743 Restlessness Diseases 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
241000906446 Theraps Species 0.000 description 1
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
208000014306 Trophic disease Diseases 0.000 description 1
206010046996 Varicose vein Diseases 0.000 description 1
208000006906 Vascular Ring Diseases 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
229920000392 Zymosan Polymers 0.000 description 1
YSVZGWAJIHWNQK-UHFFFAOYSA-N [3-(hydroxymethyl)-2-bicyclo[2.2.1]heptanyl]methanol Chemical compound C1CC2C(CO)C(CO)C1C2 YSVZGWAJIHWNQK-UHFFFAOYSA-N 0.000 description 1
KCRIFPXXOFXKSR-UHFFFAOYSA-N [5-(4,9-dioxobenzo[f][1,3]benzothiazol-2-yl)furan-2-yl]methyl acetate Chemical compound O1C(COC(=O)C)=CC=C1C1=NC(C(C2=CC=CC=C2C2=O)=O)=C2S1 KCRIFPXXOFXKSR-UHFFFAOYSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
210000003815 abdominal wall Anatomy 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 1
CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
229960004373 acetylcholine Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
HIGRAKVNKLCVCA-UHFFFAOYSA-N alumine Chemical compound C1=CC=[Al]C=C1 HIGRAKVNKLCVCA-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
BLBQQEGAFVLNJA-UHFFFAOYSA-N argon sulfane Chemical compound S.[Ar] BLBQQEGAFVLNJA-UHFFFAOYSA-N 0.000 description 1
210000001841 basilar artery Anatomy 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
229910002091 carbon monoxide Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
210000001627 cerebral artery Anatomy 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000002508 compound effect Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
230000009989 contractile response Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000036576 dermal application Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
239000012156 elution solvent Substances 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
238000011067 equilibration Methods 0.000 description 1
229960003699 evans blue Drugs 0.000 description 1
230000005284 excitation Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000006260 foam Substances 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
CNUDBTRUORMMPA-UHFFFAOYSA-N formylthiophene Chemical compound O=CC1=CC=CS1 CNUDBTRUORMMPA-UHFFFAOYSA-N 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
230000004927 fusion Effects 0.000 description 1
239000008246 gaseous mixture Substances 0.000 description 1
238000003304 gavage Methods 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000001033 granulometry Methods 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000004968 inflammatory condition Effects 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
KQPYUDDGWXQXHS-UHFFFAOYSA-N juglone Chemical compound O=C1C=CC(=O)C2=C1C=CC=C2O KQPYUDDGWXQXHS-UHFFFAOYSA-N 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000845 maltitol Substances 0.000 description 1
235000010449 maltitol Nutrition 0.000 description 1
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
229940035436 maltitol Drugs 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000028161 membrane depolarization Effects 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
230000004089 microcirculation Effects 0.000 description 1
239000004531 microgranule Substances 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
235000011929 mousse Nutrition 0.000 description 1
150000002791 naphthoquinones Chemical class 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
231100000065 noncytotoxic Toxicity 0.000 description 1
230000002020 noncytotoxic effect Effects 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002916 oxazoles Chemical class 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
208000035824 paresthesia Diseases 0.000 description 1
239000002245 particle Substances 0.000 description 1
238000005453 pelletization Methods 0.000 description 1
210000003899 penis Anatomy 0.000 description 1
229960002275 pentobarbital sodium Drugs 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
210000003281 pleural cavity Anatomy 0.000 description 1
210000004910 pleural fluid Anatomy 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
ZRHANBBTXQZFSP-UHFFFAOYSA-M potassium;4-amino-3,5,6-trichloropyridine-2-carboxylate Chemical compound [K+].NC1=C(Cl)C(Cl)=NC(C([O-])=O)=C1Cl ZRHANBBTXQZFSP-UHFFFAOYSA-M 0.000 description 1
238000002953 preparative HPLC Methods 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 1
238000011002 quantification Methods 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
210000005245 right atrium Anatomy 0.000 description 1
229910001923 silver oxide Inorganic materials 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000003068 static effect Effects 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
150000003557 thiazoles Chemical class 0.000 description 1
CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical class OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000000870 ultraviolet spectroscopy Methods 0.000 description 1
208000027185 varicose disease Diseases 0.000 description 1
230000008728 vascular permeability Effects 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
- C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
- C07C225/30—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of condensed quinone ring systems formed by two rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C46/00—Preparation of quinones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/24—Quinones containing halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/32—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having two rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/60—Naphthoxazoles; Hydrogenated naphthoxazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/84—Naphthothiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/12—One of the condensed rings being a six-membered aromatic ring the other ring being at least seven-membered

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

OA9800080A 1995-12-12 1998-06-12 Utilisation de dérivés tricycliques du 1,4-dihydro-1,4-dioxo 1h-naphtalène, nouveaux composés obtenus et leur application en thérapeutique. OA10696A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9514683A FR2742153B1 (fr)	1995-12-12	1995-12-12	Utilisation de derives tricycliques du 1,4-dihydro-1,4- dioxo-1h-naphtalene, nouveaux composes obtenus et leur application en therapeutique

Publications (1)

Publication Number	Publication Date
OA10696A true OA10696A (fr)	2002-11-26

Family

ID=9485393

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA9800080A OA10696A (fr)	1995-12-12	1998-06-12	Utilisation de dérivés tricycliques du 1,4-dihydro-1,4-dioxo 1h-naphtalène, nouveaux composés obtenus et leur application en thérapeutique.

Country Status (26)

Country	Link
US (1)	US6262095B1 (de)
EP (1)	EP0876356B1 (de)
JP (1)	JP2000501724A (de)
KR (1)	KR19990072080A (de)
AP (1)	AP889A (de)
AR (1)	AR005054A1 (de)
AT (1)	ATE207907T1 (de)
AU (1)	AU716199B2 (de)
BR (1)	BR9611935A (de)
CA (1)	CA2240279A1 (de)
CZ (1)	CZ181198A3 (de)
DE (1)	DE69616598D1 (de)
EE (1)	EE9800174A (de)
FR (1)	FR2742153B1 (de)
HU (1)	HUP9901247A3 (de)
ID (1)	ID16081A (de)
IL (1)	IL124558A0 (de)
LT (1)	LT4491B (de)
LV (1)	LV12188B (de)
NO (1)	NO982696L (de)
NZ (1)	NZ323967A (de)
OA (1)	OA10696A (de)
PL (1)	PL327168A1 (de)
RU (1)	RU2178791C2 (de)
TR (1)	TR199801069T2 (de)
WO (1)	WO1997021684A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003999A (en) *	1997-12-19	1999-07-12	Advanced Research And Technology Institute, Inc.	Modulators of ryanodine receptors comprising 2-(aryl)-4,7-dioxobenzothiazoles and analogues thereof
ES2257461T3 (es) *	2000-12-21	2006-08-01	Bristol-Myers Squibb Company	Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
TWI402261B (zh)	2006-06-19	2013-07-21	Takeda Pharmaceutical	三環化合物及其醫藥組成物
WO2007149484A2 (en)	2006-06-20	2007-12-27	Dana-Farber Cancer Institute	Inhibitors of usp1 deubiquitinating enzyme complex
WO2011137320A2 (en)	2010-04-30	2011-11-03	Dana-Farber Cancer Institute, Inc.	Small molecule inhibitors of usp1 deubiquitinating enzyme activity
US9040713B2 (en) *	2010-09-27	2015-05-26	Emory University	Methods of managing blood sugar levels and compositions related thereto
US9725425B1 (en)	2014-02-25	2017-08-08	Dana-Farber Cancer Institute, Inc.	Compounds and methods for treating cancer
RU2545091C1 (ru) *	2014-03-18	2015-03-27	Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Российской академии медицинских наук (ФГБУ "РОНЦ им. Н.Н. Блохина" РАМН)	1-R-4,9-ДИОКСО-1H-НАФТО[2,3-d][1,2,3]ТРИАЗОЛ-4-ОКСИМ-2-ОКСИДЫ И ИХ ПРОИЗВОДНЫЕ, ОБЛАДАЮЩИЕ ЦИТОТОКСИЧЕСКОЙ АКТИВНОСТЬЮ
WO2017106624A1 (en)	2015-12-18	2017-06-22	The Board Of Regents Of The University Of Texas System	Napthoquinones, pro-drugs, and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3039925A (en)	1957-04-24	1962-06-19	Bayer Ag	Compositions for the treatment of tuberculosis
US4746676A (en)	1984-09-12	1988-05-24	Rorer Pharmaceutical Corporation	Carboxyalkyl dipeptide compounds
JPH05112533A (ja) *	1991-05-08	1993-05-07	Upjohn Co:The	イミダゾベンゾキノン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
WO1994003439A1 (en) *	1992-07-29	1994-02-17	Agouron Pharmaceuticals, Inc.	Antiproliferative tricyclic compounds

1995
- 1995-12-12 FR FR9514683A patent/FR2742153B1/fr not_active Expired - Fee Related
1996
- 1996-12-10 TR TR1998/01069T patent/TR199801069T2/xx unknown
- 1996-12-10 CZ CZ981811A patent/CZ181198A3/cs unknown
- 1996-12-10 RU RU98113147/04A patent/RU2178791C2/ru active
- 1996-12-10 JP JP9521799A patent/JP2000501724A/ja active Pending
- 1996-12-10 EP EP96941734A patent/EP0876356B1/de not_active Expired - Lifetime
- 1996-12-10 US US09/043,831 patent/US6262095B1/en not_active Expired - Fee Related
- 1996-12-10 CA CA002240279A patent/CA2240279A1/fr not_active Abandoned
- 1996-12-10 DE DE69616598T patent/DE69616598D1/de not_active Expired - Lifetime
- 1996-12-10 PL PL96327168A patent/PL327168A1/xx unknown
- 1996-12-10 AP APAP/P/1998/001275A patent/AP889A/en active
- 1996-12-10 BR BR9611935A patent/BR9611935A/pt unknown
- 1996-12-10 WO PCT/FR1996/001973 patent/WO1997021684A1/fr not_active Ceased
- 1996-12-10 AU AU11018/97A patent/AU716199B2/en not_active Ceased
- 1996-12-10 EE EE9800174A patent/EE9800174A/xx unknown
- 1996-12-10 AT AT96941734T patent/ATE207907T1/de not_active IP Right Cessation
- 1996-12-10 NZ NZ323967A patent/NZ323967A/en unknown
- 1996-12-10 IL IL12455896A patent/IL124558A0/xx unknown
- 1996-12-10 HU HU9901247A patent/HUP9901247A3/hu unknown
- 1996-12-10 KR KR1019980704387A patent/KR19990072080A/ko not_active Ceased
- 1996-12-12 ID IDP963710A patent/ID16081A/id unknown
- 1996-12-12 AR ARP960105648A patent/AR005054A1/es unknown
1998
- 1998-06-10 LT LT98-085A patent/LT4491B/lt not_active IP Right Cessation
- 1998-06-11 NO NO982696A patent/NO982696L/no not_active Application Discontinuation
- 1998-06-12 OA OA9800080A patent/OA10696A/fr unknown
- 1998-06-12 LV LVP-98-136A patent/LV12188B/en unknown

Also Published As

Publication number	Publication date
EP0876356B1 (de)	2001-10-31
LV12188B (en)	1999-07-20
WO1997021684A1 (fr)	1997-06-19
NO982696D0 (no)	1998-06-11
LT4491B (lt)	1999-04-26
CZ181198A3 (cs)	1998-09-16
AU1101897A (en)	1997-07-03
AU716199B2 (en)	2000-02-24
RU2178791C2 (ru)	2002-01-27
AP9801275A0 (en)	1998-06-30
NZ323967A (en)	2000-06-23
FR2742153A1 (fr)	1997-06-13
LT98085A (en)	1998-11-25
ID16081A (id)	1997-09-04
AP889A (en)	2000-11-17
EP0876356A1 (de)	1998-11-11
FR2742153B1 (fr)	1998-02-13
US6262095B1 (en)	2001-07-17
ATE207907T1 (de)	2001-11-15
IL124558A0 (en)	1998-12-06
NO982696L (no)	1998-08-11
BR9611935A (pt)	1999-05-18
HUP9901247A2 (hu)	1999-08-30
CA2240279A1 (fr)	1997-06-19
TR199801069T2 (xx)	1998-08-21
JP2000501724A (ja)	2000-02-15
PL327168A1 (en)	1998-11-23
DE69616598D1 (de)	2001-12-06
KR19990072080A (ko)	1999-09-27
EE9800174A (et)	1998-12-15
AR005054A1 (es)	1999-04-07
LV12188A (lv)	1998-12-20
HUP9901247A3 (en)	2000-08-28

Publication	Publication Date	Title
KR910005709B1 (ko)	1991-08-02	벤조티아졸 유도체
RU2336274C2 (ru)	2008-10-20	Замещенные 3-цианотиофенацетамиды в качестве антагонистов рецептора глюкагона
CA2150162C (fr)	2002-05-14	Nouveau n-pyridyl carboxamides et derives, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
EP3418273B1 (de)	2022-01-12	Flavaglin-derivate
MC937A1 (fr)	1973-08-10	Procédé de préparations d'inhibiteurs de xanthine-oxydase
EP0690050A1 (de)	1996-01-03	(Thia)cycloalkyl(b)indolderivate als 5-lipoxygenase Inhibitoren
EP0876356B1 (de)	2001-10-31	Verwendung von tricyclischen 1,4-dihydro-1,4-dioxo-1h-naphalen derivaten, neue verbindungen und ihre therapeutische verwendung
EP0503471A1 (de)	1992-09-16	Neue acylaminosubstituierte Hetrazepine
WO2010029986A1 (ja)	2010-03-18	スルホン酸エステル構造を導入したフェニル基を置換基として有する新規１，２，３，４－テトラヒドロキノキサリン誘導体からなるグルココルチコイド受容体アゴニスト
FR2742155A1 (fr)	1997-06-13	Utilisation de derives heteroaromatiques et tricycliques du 1,4-dihydro-1,4-dioxonaphtalene, nouveaux composes obtenus et leur application en therapeutique
FR2742151A1 (fr)	1997-06-13	Utilisation de derives de bicycles mono ou dicetoniques, nouveaux composes obtenus et leur application en therapeutique
FR2803299A1 (fr)	2001-07-06	NOUVELLES PYRAZOLO [4,3-e] DIAZEPINES SUBSTITUEES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
CA2557942C (fr)	2013-08-06	Derives de carbamate de 2h- ou 3h-benzo[e]indazol-1-yle, leur preparation et leur application en therapeutique
EP0646579A1 (de)	1995-04-05	Ketonische Indan Derivate und heterozyklische Analogen und ihre Anwendung in der Therapie
EP0098204A1 (de)	1984-01-11	Therapeutische Zusammensetzungen die N-substituierte Hydrazone enthalten und N-substituierte Hydrazone
WO1997021709A1 (fr)	1997-06-19	Utilisation de derives de tetracycles mono ou dicetoniques, nouveaux composes obtenus et leur application en therapeutique
MXPA98004717A (es)	1999-07-06	Utilizacion de derivados triciclicos de 1,4-dihidro-1,4-dioxo-1h-naftaleno, nuevos compuestos obtenidos y su aplicacion terapeutica
SK289100B6 (sk)	2023-08-09	Zlúčenina cemtirestat disulfid, prekurzor inhibítora aldoketoreduktáz, spôsob jej prípravy, farmaceutický prostriedok s jej obsahom a jej použitie
JP2922930B2 (ja)	1999-07-26	ヒダントイン誘導体及びその用途
FR2764292A1 (fr)	1998-12-11	Utilisation de derives de tetracycles dicetoniques, nouveaux composes obtenus et leur application en therapeutique
EP0646574A1 (de)	1995-04-05	Ketonderivate des Indans, ihre Herstellung und ihre therapeutische Anwendung